ArticleJournal of intensive care2019
The wind changed direction and the big river still flows: from EUPHRATES to TIGRIS.
Article in Journal of intensive care, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04884854 (Early Efferon LPS Hemoperfusion Through Hypercrosslinked Styrene-divinylbenzene Copolymer With Immobilized LPS-selective Ligand for Treatment of Patients With Septic Shock), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Early Efferon LPS Hemoperfusion Through Hypercrosslinked Styrene-divinylbenzene Copolymer With Immobilized LPS-selective Ligand for Treatment of Patients With Septic Shock
Who cites it
15 citing papers in PubMed.
- Precision medicine in sepsis: lessons from the TIGRIS trial and the reawakening of targeted therapy.Journal of anesthesia, analgesia and critical care · 2026Review
- Differential Impact of Polymyxin B Hemadsorption on Long-Term Mortality in Septic Shock: A Retrospective Analysis of Intra-Abdominal Versus Extra-Abdominal Infections.Artificial organs · 2026Article
- TIGRIS and EUPHRATES eventually join and provide new evidence: a narrative review of the polymyxin B hemoperfusion.Journal of intensive care · 2025Review
- Research Progress on Signalling Pathways Related to Sepsis-Associated Acute Kidney Injury in Children.Current issues in molecular biology · 2025Review
- Polymyxin B Hemoperfusion for Patients With Septic Shock Requiring High-Dose Norepinephrine: A Multicenter Prospective Cohort Study.Critical care explorations · 2025Article
- Endotoxin Hemoperfusion as an Adjuvant Therapy for Sepsis: Lessons from the TIGRIS Trial.Juntendo medical journal · 2025Review
- Sepsis-Associated Acute Kidney Injury: Where Are We Now?Medicina (Kaunas, Lithuania) · 2024Review
- Endotoxin removal therapy with Polymyxin B immobilized fiber column: a single center experience from EUPHAS2 registry.Scientific reports · 2023Observational
- Blood Purification in Patients with Sepsis Associated with Acute Kidney Injury: A Narrative Review.Journal of clinical medicine · 2023Review
- Potential survival benefit and early recovery from organ dysfunction with polymyxin B hemoperfusion: perspectives from a real-world big data analysis and the supporting mechanisms of action.Journal of anesthesia, analgesia and critical care · 2022Review
- Blood purification in sepsis and COVID-19: what´s new in cytokine and endotoxin hemoadsorption.Journal of anesthesia, analgesia and critical care · 2022Review
- Precision medicine in sepsis and septic shock: From omics to clinical tools.World journal of critical care medicine · 2022Review
- Effectiveness of polymyxin B hemoperfusion for sepsis depends on the baseline SOFA score: a nationwide observational study.Annals of intensive care · 2021Article
- Surviving Sepsis Campaign: Research Opportunities for Infection and Blood Purification Therapies.Critical care explorations · 2021Review
- Is an EAA > 0.6 in severe COVID-19 patients synonymous with a toxic and pro-inflammatory endotoxin profile, and should we treat it?Intensive care medicine experimental · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The overall result of the randomized controlled double-blinded trial for polymyxin B-immobilized fiber column on septic shock (EUPHRATES trial) was disappointing. However, post hoc analysis showed benefits for patients with certain Endotoxin Activity Assay (EAA) levels. Thus, the study will be repeated, and the data will be added to the former trial. Using a precision medicine approach, eligibility criteria have been modified in TIGRIS to include patients with MODS score > 9 and EAA levels between 0.60 and 0.89. We are currently feeling the change in the wind as the rivers continue to flow towards PMX therapy for endotoxemic septic shock.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.